FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:977-987 September 8, 2005 Number 10 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Baden, L. R. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The prophylactic use of fluoroquinolones in patients with cancer and neutropenia is controversial and is not a recommended intervention.

Methods We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resolution of neutropenia. Patients were stratified according to their underlying disease (acute leukemia vs. solid tumor or lymphoma).

Results An intention-to-treat analysis showed that fever was present for the duration of neutropenia in 65 percent of patients who received levofloxacin prophylaxis, as compared with 85 percent of those receiving placebo (243 of 375 vs. 308 of 363; relative risk, 0.76; absolute difference in risk, –20 percent; 95 percent confidence interval, –26 to –14 percent; P=0.001). The levofloxacin group had a lower rate of microbiologically documented infections (absolute difference in risk, –17 percent; 95 percent confidence interval, –24 to –10 percent; P<0.001), bacteremias (difference in risk, –16 percent; 95 percent confidence interval, –22 to –9 percent; P<0.001), and single-agent gram-negative bacteremias (difference in risk, –7 percent; 95 percent confidence interval, –10 to –2 percent; P<0.01) than did the placebo group. Mortality and tolerability were similar in the two groups. The effects of prophylaxis were also similar between patients with acute leukemia and those with solid tumors or lymphoma.

Conclusions Prophylactic treatment with levofloxacin is an effective and well-tolerated way of preventing febrile episodes and other relevant infection-related outcomes in patients with cancer and profound and protracted neutropenia. The long-term effect of this intervention on microbial resistance in the community is not known.

Source Information

From Policlinico Monteluce, Perugia (G.B., M.S.D., A.D.F.); Università La Sapienza, Rome (A.M., P.M., R.F.); Ospedale Cisanello, Pisa (F.M.); Istituto Oncologico Europeo, Milan (G.M.); Ospedale Santi Antonio e Biagio, Alessandria (B.A.); Ospedale Civile Santo Spirito, Pescara (D.D.); Ospedali Riuniti di Bergamo, Bergamo (M.B.); Ospedale Niguarda, Milan (A.M.N.); Ospedale San Luigi, Orbassano (D.C.); Ospedale Santa Maria delle Croci, Ravenna (E.Z.); Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro (R.C.); Università di Bari, Bari (G.S.); Ospedale Sant' Eugenio, Rome (S.A.); Azienda Ospedaliera Cervello, Palermo (F.F.); Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale Maggiore, Milan (G.L.D.); and Policlinico Le Scotte, Siena (F.L.) — all in Italy.

Address reprint requests to Dr. Del Favero at the Istituto di Medicina Interna e Scienze Oncologiche, Università di Perugia, Policlinico Monteluce, 06100 Perugia, Italy, or at delfa{at}unipg.it.

Full Text of this Article

Related Letters:

Antibacterial Prophylaxis in Patients with Cancer and Neutropenia
Freifeld A. G., Sepkowitz K. A., Almyroudis N. G., Segal B. H., Castagna L., Santoro A., Pasqualotto A. C., Rosa D. D., Machado A. L., Ito J. I., Tegtmeier B. R., O'Donnell M. R., Eller P., Pechlaner C., Del Favero A., Bucaneve G., Martino P., Steven N., Billingham L., Cullen M., Baden L. R.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:90-94, Jan 5, 2006. Correspondence

This article has been cited by other articles:

• Mielcarek, M., Storer, B. E., Boeckh, M., Carpenter, P. A., McDonald, G. B., Deeg, H. J., Nash, R. A., Flowers, M. E. D., Doney, K., Lee, S., Marr, K. A., Furlong, T., Storb, R., Appelbaum, F. R., Martin, P. J. (2009). Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 113: 2888-2894 [Abstract] [Full Text]  
• Tanimoto, K., Tomita, H., Fujimoto, S., Okuzumi, K., Ike, Y. (2008). Fluoroquinolone Enhances the Mutation Frequency for Meropenem-Selected Carbapenem Resistance in Pseudomonas aeruginosa, but Use of the High-Potency Drug Doripenem Inhibits Mutant Formation. Antimicrob. Agents Chemother. 52: 3795-3800 [Abstract] [Full Text]  
• Cattaneo, C., Quaresmini, G., Casari, S., Capucci, M. A., Micheletti, M., Borlenghi, E., Signorini, L., Re, A., Carosi, G., Rossi, G. (2008). Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 61: 721-728 [Abstract] [Full Text]  
• Cullen, M. H., Billingham, L. J., Gaunt, C. H., Steven, N. M. (2007). Rational Selection of Patients for Antibacterial Prophylaxis After Chemotherapy. JCO 25: 4821-4828 [Abstract] [Full Text]  
• Halim, T., Song, K., Barnett, M., Forrest, D., Hogge, D., Nantel, S., Nevill, T., Shepherd, J., Smith, C., Sutherland, H., Toze, C., Lavoie, J. (2007). Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia. Ann Oncol 18: 1246-1252 [Abstract] [Full Text]  
• Gafter-Gvili, A., Paul, M., Fraser, A., Leibovici, L. (2007). Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 59: 5-22 [Abstract] [Full Text]  
• von Baum, H., Sigge, A., Bommer, M., Kern, W. V., Marre, R., Dohner, H., Kern, P., Reuter, S. (2006). Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 58: 891-894 [Abstract] [Full Text]  
• Schouten, H. C. (2006). Home treatment for intensive hematological therapies: who will benefit?. Ann Oncol 17: 731-732 [Full Text]  
• (2006). ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB. Evid. Based Med. 11: 62-62 [Full Text]  
• Dunleavy, K., Wilson, W. H., Kaplan, L. D. (2006). The case for rituximab in AIDS-related lymphoma.. Blood 107: 3014-3015 [Full Text]  
• Shalit, I., Halperin, D., Haite, D., Levitov, A., Romano, J., Osherov, N., Fabian, I. (2006). Anti-inflammatory effects of moxifloxacin on IL-8, IL-1{beta} and TNF-{alpha} secretion and NF{kappa}B and MAP-kinase activation in human monocytes stimulated with Aspergillus fumigatus. J Antimicrob Chemother 57: 230-235 [Abstract] [Full Text]  
• Freifeld, A. G., Sepkowitz, K. A., Almyroudis, N. G., Segal, B. H., Castagna, L., Santoro, A., Pasqualotto, A. C., Rosa, D. D., Machado, A. L., Ito, J. I., Tegtmeier, B. R., O'Donnell, M. R., Eller, P., Pechlaner, C., Del Favero, A., Bucaneve, G., Martino, P., Steven, N., Billingham, L., Cullen, M., Baden, L. R. (2006). Antibacterial prophylaxis in patients with cancer and neutropenia.. NEJM 354: 90-94 [Full Text]  
• (2005). Prophylactic Levofloxacin for Neutropenic Cancer Patients?. JWatch Infect. Diseases 2005: 7-7 [Full Text]  
• (2005). Levofloxacin Averts Infections During Chemotherapy-Induced Neutropenia. JWatch General 2005: 3-3 [Full Text]  
• Cullen, M., Steven, N., Billingham, L., Gaunt, C., Hastings, M., Simmonds, P., Stuart, N., Rea, D., Bower, M., Fernando, I., Huddart, R., Gollins, S., Stanley, A., the Simple Investigation in Neutropenic Individual, (2005). Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas. NEJM 353: 988-998 [Abstract] [Full Text]  
• Baden, L. R. (2005). Prophylactic Antimicrobial Agents and the Importance of Fitness. NEJM 353: 1052-1054 [Full Text]